Incidence of SARS-CoV-2 Infection Among European Healthcare Workers and Effectiveness of the First Booster COVID-19 Vaccine, VEBIS HCW Observational Cohort Study, May 2021-May 2023.
Savulescu C., Prats-Uribe A., Brolin K., Lovrić Makarić Z., Uusküla A., Panagiotakopoulos G., Bergin C., Fleming C., Agodi A., Bonfanti P., Murri R., Zvirbulis V., Zavadska D., Szuldrzynski K., Machado A., Popescu CP., Craiu M., Cisneros M., Latorre-Millán M., Petrović G., Lohur L., Tryfinopoulou K., McGrath J., Ferguson L., Barchitta M., Spolti A., de Gaetano Donati K., Abolina I., Gravele D., Gaio V., Florescu SA., Lazar M., Subirats P., Clusa Cuesta L., Sarajlić G., Amerali M., Sui J., Kenny C., Rapisarda V., Rossi M., Lamonica S., Krievins D., Barzdina EA., Palmira Amaral A., Kosa AG., Miron VD., Muñoz-Almagro C., Milagro AM., Bacci S., Kramarz P., Nardone A., The Vebis Hcw Ve Study Group None.
Background: European countries have included healthcare workers (HCWs) among priority groups for COVID-19 vaccination. We established a multi-country hospital network to measure the SARS-CoV-2 incidence and effectiveness of COVID-19 vaccines among HCWs against laboratory-confirmed SARS-CoV-2 infection. Methods: HCWs from 19 hospitals in 10 countries participated in a dynamic prospective cohort study, providing samples for SARS-CoV-2 testing at enrolment and during weekly/fortnightly follow-up. We measured the incidence during pre-Delta (2 May-6 September 2021), Delta (7 September-14 December 2021), and Omicron (15 December 2021-2 May 2023) waves. Using Cox regression, we measured the relative vaccine effectiveness (rVE) of the first COVID-19 booster dose versus primary course alone during Delta and Omicron waves. Results: We included a total of 3015 HCWs. Participants were mostly female (2306; 79%), with a clinical role (2047; 68%), and had a median age of 44 years. The overall incidence of SARS-CoV-2 infection was 3.01/10,000 person-days during pre-Delta, 4.21/10,000 during Delta, and 23.20/10,000 during Omicron waves. rVE was 59% (95% CI: -25; 86) during Delta and 22% (1; 39) during Omicron waves. rVE was 51% (30; 65) 7-90 days after the first booster dose during the Omicron wave. Conclusions: The incidence of SARS-CoV-2 infection among HCWs was higher during the Omicron circulation period. The first COVID-19 vaccine booster provided additional protection against SARS-CoV-2 infection compared to primary course vaccination when recently vaccinated <90 days. This multi-country HCW cohort study addressing infection as the main outcome is crucial for informing public health interventions for HCWs.